Invitae : JP Morgan 2021 presentation

From genetics, health

J.P. Morgan Healthcare Conference

01 | 12 | 21

Safe harbor statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding the shift to universal testing for all, and the timing, value and benefits of such a shift; the company's beliefs regarding its business, including the impact and benefits of its technology, menu, services, platform, team and ecosystem, and its ability to execute; the company's belief regarding the momentum of its business and ability to continue to deliver on its mission to bring genetic information into mainstream medicine; the impact of the company's acquisitions, as well as its internal development efforts, partnerships and product offerings; the company's beliefs regarding the size of various markets and market penetration; the benefits of the company's business strategy; and the company's beliefs regarding its ability to access new and developing markets, improve ease-of- use for customers, and meet the needs of patients and clinicians. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the impact of COVID-19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

© 2021 Invitae Corporation. All Rights Reserved.

2

Invitae's mission is to bring comprehensive genetics into mainstream medicine to improve healthcare for billions of people

© 2021 Invitae Corporation. All Rights Reserved.

3

3

Single greatest shift in medicine and healthcare

"Modern" medicine
Chemotherapy standard of care
Newborn diagnosis after birth
Symptom-based, universally applied		Universal testing for all
		Risk information = effective prevention
		Earliest detection = disease eradication
		Personalized therapy and biomarker driven
		monitoring
		Gene-informed healthcare throughout life

© 2021 Invitae Corporation. All Rights Reserved.

4